Risk of heart failure among postmenopausal women a secondary analysis of the randomized trial of Vitamin D plus calcium of the women's health initiative

Macarius M. Donneyong, Carlton A. Hornung, Kira C. Taylor, Richard N. Baumgartner, John A. Myers, Charles B. Eaton, Eiran Z. Gorodeski, Liviu Klein, Lisa W. Martin, James M. Shikany, Yiqing Song, Wenjun Li, Jo Ann E. Manson

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background-Vitamin D supplementation may be an inexpensive intervention to reduce heart failure (HF) incidence. However, there are insufficient data to support this hypothesis. This study evaluates whether vitamin D plus calcium (CaD) supplementation is associated with lower rates of HF in postmenopausal women and whether the effects differ between those at high versus low risk for HF. Methods and Results-Analyses were restricted to 35 983 (of original 36 282) women aged 50 to 79 years old in the Women's Health Initiative randomized trial of CaD supplementation who were randomized 1:1 in a double-blinded fashion to receive 1000 mg/d of calcium plus 400 IU/d of vitamin D3 or placebo. Overall, 744 adjudicated incident HF cases (intervention, 363; control, 381) occurred during a median follow-up of 7.1 (interquartile range, 1.6) years. CaD supplementation, compared with placebo, was not associated with reduced HF risk in the overall population, hazard ratio, 0.95; P=0.46. However, CaD supplementation had differential effects (P interaction=0.005) in subgroups stratified by baseline risk status of HF defined by the presence (high risk=17 449) or absence (low risk=18 534) of pre-existing HF precursors including coronary heart diseases, diabetes mellitus, or hypertension: 37% (hazard ratio, 0.63 [95% confidence interval, 0.460.87]) lower risk of HF in the low-risk versus hazard ratio, 1.06; P=0.51, in the high-risk subgroups. Conclusions-CaD supplementation did not significantly reduce HF incidence in the overall cohort, however, it was beneficial among postmenopausal women without major HF precursors while of little value in high-risk subgroups. Additional studies are warranted to confirm these findings and investigate the underlying mechanism.

Original languageEnglish (US)
Pages (from-to)49-56
Number of pages8
JournalCirculation: Heart Failure
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Women's Health
Vitamin D
Heart Failure
Calcium
Placebos
Cholecalciferol
Incidence
Coronary Disease
Diabetes Mellitus
Confidence Intervals
Hypertension

Keywords

  • Calcium
  • Clinical trial
  • Heart failure
  • Vitamin D
  • Women

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Risk of heart failure among postmenopausal women a secondary analysis of the randomized trial of Vitamin D plus calcium of the women's health initiative. / Donneyong, Macarius M.; Hornung, Carlton A.; Taylor, Kira C.; Baumgartner, Richard N.; Myers, John A.; Eaton, Charles B.; Gorodeski, Eiran Z.; Klein, Liviu; Martin, Lisa W.; Shikany, James M.; Song, Yiqing; Li, Wenjun; Manson, Jo Ann E.

In: Circulation: Heart Failure, Vol. 8, No. 1, 01.01.2015, p. 49-56.

Research output: Contribution to journalArticle

Donneyong, MM, Hornung, CA, Taylor, KC, Baumgartner, RN, Myers, JA, Eaton, CB, Gorodeski, EZ, Klein, L, Martin, LW, Shikany, JM, Song, Y, Li, W & Manson, JAE 2015, 'Risk of heart failure among postmenopausal women a secondary analysis of the randomized trial of Vitamin D plus calcium of the women's health initiative', Circulation: Heart Failure, vol. 8, no. 1, pp. 49-56. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001738
Donneyong, Macarius M. ; Hornung, Carlton A. ; Taylor, Kira C. ; Baumgartner, Richard N. ; Myers, John A. ; Eaton, Charles B. ; Gorodeski, Eiran Z. ; Klein, Liviu ; Martin, Lisa W. ; Shikany, James M. ; Song, Yiqing ; Li, Wenjun ; Manson, Jo Ann E. / Risk of heart failure among postmenopausal women a secondary analysis of the randomized trial of Vitamin D plus calcium of the women's health initiative. In: Circulation: Heart Failure. 2015 ; Vol. 8, No. 1. pp. 49-56.
@article{8a5dcab7d2ad4bccb4bc3e36dca44adb,
title = "Risk of heart failure among postmenopausal women a secondary analysis of the randomized trial of Vitamin D plus calcium of the women's health initiative",
abstract = "Background-Vitamin D supplementation may be an inexpensive intervention to reduce heart failure (HF) incidence. However, there are insufficient data to support this hypothesis. This study evaluates whether vitamin D plus calcium (CaD) supplementation is associated with lower rates of HF in postmenopausal women and whether the effects differ between those at high versus low risk for HF. Methods and Results-Analyses were restricted to 35 983 (of original 36 282) women aged 50 to 79 years old in the Women's Health Initiative randomized trial of CaD supplementation who were randomized 1:1 in a double-blinded fashion to receive 1000 mg/d of calcium plus 400 IU/d of vitamin D3 or placebo. Overall, 744 adjudicated incident HF cases (intervention, 363; control, 381) occurred during a median follow-up of 7.1 (interquartile range, 1.6) years. CaD supplementation, compared with placebo, was not associated with reduced HF risk in the overall population, hazard ratio, 0.95; P=0.46. However, CaD supplementation had differential effects (P interaction=0.005) in subgroups stratified by baseline risk status of HF defined by the presence (high risk=17 449) or absence (low risk=18 534) of pre-existing HF precursors including coronary heart diseases, diabetes mellitus, or hypertension: 37{\%} (hazard ratio, 0.63 [95{\%} confidence interval, 0.460.87]) lower risk of HF in the low-risk versus hazard ratio, 1.06; P=0.51, in the high-risk subgroups. Conclusions-CaD supplementation did not significantly reduce HF incidence in the overall cohort, however, it was beneficial among postmenopausal women without major HF precursors while of little value in high-risk subgroups. Additional studies are warranted to confirm these findings and investigate the underlying mechanism.",
keywords = "Calcium, Clinical trial, Heart failure, Vitamin D, Women",
author = "Donneyong, {Macarius M.} and Hornung, {Carlton A.} and Taylor, {Kira C.} and Baumgartner, {Richard N.} and Myers, {John A.} and Eaton, {Charles B.} and Gorodeski, {Eiran Z.} and Liviu Klein and Martin, {Lisa W.} and Shikany, {James M.} and Yiqing Song and Wenjun Li and Manson, {Jo Ann E.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.114.001738",
language = "English (US)",
volume = "8",
pages = "49--56",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Risk of heart failure among postmenopausal women a secondary analysis of the randomized trial of Vitamin D plus calcium of the women's health initiative

AU - Donneyong, Macarius M.

AU - Hornung, Carlton A.

AU - Taylor, Kira C.

AU - Baumgartner, Richard N.

AU - Myers, John A.

AU - Eaton, Charles B.

AU - Gorodeski, Eiran Z.

AU - Klein, Liviu

AU - Martin, Lisa W.

AU - Shikany, James M.

AU - Song, Yiqing

AU - Li, Wenjun

AU - Manson, Jo Ann E.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background-Vitamin D supplementation may be an inexpensive intervention to reduce heart failure (HF) incidence. However, there are insufficient data to support this hypothesis. This study evaluates whether vitamin D plus calcium (CaD) supplementation is associated with lower rates of HF in postmenopausal women and whether the effects differ between those at high versus low risk for HF. Methods and Results-Analyses were restricted to 35 983 (of original 36 282) women aged 50 to 79 years old in the Women's Health Initiative randomized trial of CaD supplementation who were randomized 1:1 in a double-blinded fashion to receive 1000 mg/d of calcium plus 400 IU/d of vitamin D3 or placebo. Overall, 744 adjudicated incident HF cases (intervention, 363; control, 381) occurred during a median follow-up of 7.1 (interquartile range, 1.6) years. CaD supplementation, compared with placebo, was not associated with reduced HF risk in the overall population, hazard ratio, 0.95; P=0.46. However, CaD supplementation had differential effects (P interaction=0.005) in subgroups stratified by baseline risk status of HF defined by the presence (high risk=17 449) or absence (low risk=18 534) of pre-existing HF precursors including coronary heart diseases, diabetes mellitus, or hypertension: 37% (hazard ratio, 0.63 [95% confidence interval, 0.460.87]) lower risk of HF in the low-risk versus hazard ratio, 1.06; P=0.51, in the high-risk subgroups. Conclusions-CaD supplementation did not significantly reduce HF incidence in the overall cohort, however, it was beneficial among postmenopausal women without major HF precursors while of little value in high-risk subgroups. Additional studies are warranted to confirm these findings and investigate the underlying mechanism.

AB - Background-Vitamin D supplementation may be an inexpensive intervention to reduce heart failure (HF) incidence. However, there are insufficient data to support this hypothesis. This study evaluates whether vitamin D plus calcium (CaD) supplementation is associated with lower rates of HF in postmenopausal women and whether the effects differ between those at high versus low risk for HF. Methods and Results-Analyses were restricted to 35 983 (of original 36 282) women aged 50 to 79 years old in the Women's Health Initiative randomized trial of CaD supplementation who were randomized 1:1 in a double-blinded fashion to receive 1000 mg/d of calcium plus 400 IU/d of vitamin D3 or placebo. Overall, 744 adjudicated incident HF cases (intervention, 363; control, 381) occurred during a median follow-up of 7.1 (interquartile range, 1.6) years. CaD supplementation, compared with placebo, was not associated with reduced HF risk in the overall population, hazard ratio, 0.95; P=0.46. However, CaD supplementation had differential effects (P interaction=0.005) in subgroups stratified by baseline risk status of HF defined by the presence (high risk=17 449) or absence (low risk=18 534) of pre-existing HF precursors including coronary heart diseases, diabetes mellitus, or hypertension: 37% (hazard ratio, 0.63 [95% confidence interval, 0.460.87]) lower risk of HF in the low-risk versus hazard ratio, 1.06; P=0.51, in the high-risk subgroups. Conclusions-CaD supplementation did not significantly reduce HF incidence in the overall cohort, however, it was beneficial among postmenopausal women without major HF precursors while of little value in high-risk subgroups. Additional studies are warranted to confirm these findings and investigate the underlying mechanism.

KW - Calcium

KW - Clinical trial

KW - Heart failure

KW - Vitamin D

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=84927737473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927737473&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.114.001738

DO - 10.1161/CIRCHEARTFAILURE.114.001738

M3 - Article

VL - 8

SP - 49

EP - 56

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 1

ER -